Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved lapatinib in combination with capecitabine for reimbursement as a treatment option for the treatment of adult patients with advanced or metastatic breast cancer whose tumors overexpress HER2 with disease progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.
This is written in the approval document as:
Treatment of adult patients with breast cancer, whose tumours overexpress HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.
Citation
Lapatinib and Capecitabine Therapy, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Capecitabine, Lapatinib |